Nationwide Fund Advisors Purchases 3,651 Shares of Regenxbio Inc (RGNX)

Nationwide Fund Advisors lifted its position in shares of Regenxbio Inc (NASDAQ:RGNX) by 7.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 52,725 shares of the biotechnology company’s stock after purchasing an additional 3,651 shares during the quarter. Nationwide Fund Advisors owned approximately 0.17% of Regenxbio worth $1,737,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Legal & General Group Plc grew its holdings in shares of Regenxbio by 41.4% during the 2nd quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 2,011 shares in the last quarter. Ardsley Advisory Partners bought a new position in shares of Regenxbio during the 2nd quarter worth approximately $197,000. Voya Investment Management LLC bought a new position in shares of Regenxbio during the 2nd quarter worth approximately $249,000. Asymmetry Capital Management L.P. lifted its position in shares of Regenxbio by 12.2% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 13,906 shares of the biotechnology company’s stock worth $275,000 after buying an additional 1,508 shares during the period. Finally, Wells Fargo & Company MN lifted its position in shares of Regenxbio by 1.1% during the 2nd quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock worth $320,000 after buying an additional 175 shares during the period. 68.73% of the stock is currently owned by institutional investors.

Regenxbio Inc (NASDAQ RGNX) opened at $33.65 on Friday. Regenxbio Inc has a 52-week low of $16.30 and a 52-week high of $36.10. The stock has a market capitalization of $976.41, a price-to-earnings ratio of -12.46 and a beta of -0.85.

Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.04. Regenxbio had a negative return on equity of 39.33% and a negative net margin of 764.06%. The firm had revenue of $1.34 million during the quarter. equities analysts expect that Regenxbio Inc will post -2.71 earnings per share for the current year.

In other Regenxbio news, CFO Vittal Vasista sold 5,000 shares of Regenxbio stock in a transaction on Monday, October 16th. The stock was sold at an average price of $33.25, for a total value of $166,250.00. Following the completion of the transaction, the chief financial officer now owns 92,283 shares in the company, valued at approximately $3,068,409.75. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Donald J. Hayden, Jr. sold 20,000 shares of Regenxbio stock in a transaction on Wednesday, September 27th. The shares were sold at an average price of $32.45, for a total value of $649,000.00. Following the completion of the transaction, the director now owns 20,000 shares of the company’s stock, valued at approximately $649,000. The disclosure for this sale can be found here. In the last quarter, insiders sold 104,000 shares of company stock valued at $3,304,546. Corporate insiders own 17.00% of the company’s stock.

Several equities analysts recently commented on RGNX shares. BidaskClub upgraded Regenxbio from a “buy” rating to a “strong-buy” rating in a research report on Friday. Morgan Stanley restated an “overweight” rating and set a $34.00 target price on shares of Regenxbio in a research report on Thursday, November 9th. Chardan Capital restated a “buy” rating on shares of Regenxbio in a research report on Monday, December 11th. Bank of America raised their target price on Regenxbio from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, September 21st. Finally, Zacks Investment Research downgraded Regenxbio from a “buy” rating to a “hold” rating in a research report on Friday, November 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $42.43.

ILLEGAL ACTIVITY WARNING: “Nationwide Fund Advisors Purchases 3,651 Shares of Regenxbio Inc (RGNX)” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.com-unik.info/2017/12/24/nationwide-fund-advisors-purchases-3651-shares-of-regenxbio-inc-rgnx.html.

Regenxbio Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

What are top analysts saying about Regenxbio? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regenxbio and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit